These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 15808191)
41. Choroidal neovascularization in pathologic myopia: three-year results after photodynamic therapy. Krebs I; Binder S; Stolba U; Glittenberg C; Brannath W; Goll A Am J Ophthalmol; 2005 Sep; 140(3):416-25. PubMed ID: 16139000 [TBL] [Abstract][Full Text] [Related]
42. [Verteporfin and photosensitivity in diabetic]. Asensio Sánchez VM; Corral Azor A; García Pascual A Arch Soc Esp Oftalmol; 2003 May; 78(5):277-9. PubMed ID: 12789632 [TBL] [Abstract][Full Text] [Related]
43. [New methods of treatment of age-related macular degeneration. Photodynamic therapy. Part I]. Gierek-Łapińska A; Wykrota H; Trzciakowski K Klin Oczna; 2002; 104(3-4):276-82. PubMed ID: 12608319 [TBL] [Abstract][Full Text] [Related]
44. Anecortave acetate (15 milligrams) versus photodynamic therapy for treatment of subfoveal neovascularization in age-related macular degeneration. Slakter JS; Bochow TW; D'Amico DJ; Marks B; Jerdan J; Sullivan EK; Robertson SM; Slakter JS; Sullins G; Zilliox P; Ophthalmology; 2006 Jan; 113(1):3-13. PubMed ID: 16368146 [TBL] [Abstract][Full Text] [Related]
45. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study. Heier JS; Boyer DS; Ciulla TA; Ferrone PJ; Jumper JM; Gentile RC; Kotlovker D; Chung CY; Kim RY; Arch Ophthalmol; 2006 Nov; 124(11):1532-42. PubMed ID: 17101999 [TBL] [Abstract][Full Text] [Related]
46. Verteporfin and intravitreal triamcinolone acetonide combination therapy for occult choroidal neovascularization in age-related macular degeneration. Augustin AJ; Schmidt-Erfurth U Am J Ophthalmol; 2006 Apr; 141(4):638-45. PubMed ID: 16564797 [TBL] [Abstract][Full Text] [Related]
47. Effects of photodynamic therapy using verteporfin on experimental choroidal neovascularization and normal retina and choroid up to 7 weeks after treatment. Husain D; Kramer M; Kenny AG; Michaud N; Flotte TJ; Gragoudas ES; Miller JW Invest Ophthalmol Vis Sci; 1999 Sep; 40(10):2322-31. PubMed ID: 10476799 [TBL] [Abstract][Full Text] [Related]
54. Clinical Phenotypes of Poppers Maculopathy and Their Links to Visual and Anatomic Recovery. Van Bol LB; Kurt RA; Keane PA; Pal B; Sivaprasad S Ophthalmology; 2017 Sep; 124(9):1425-1427. PubMed ID: 28648381 [No Abstract] [Full Text] [Related]
55. Bilateral Severe Decreased Vision With Normal Examination Findings. Rayess N; Patel VR JAMA Ophthalmol; 2018 Oct; 136(10):1201-1202. PubMed ID: 30073263 [No Abstract] [Full Text] [Related]
56. Diagnostic and therapeutic challenges. Progressive bilateral visual loss over the last seven years. Drenser KA; Williams GA; Fu AD; Egan C; Hykin PG; Dugel PU; Rao PK Retina; 2005 Sep; 25(6):778-83. PubMed ID: 16141868 [No Abstract] [Full Text] [Related]
57. Acute visual loss caused by transient choroid ischemia and subretinal hyperreflective material after photodynamic therapy. Chen YC; Chen SN; Chuang CC J Formos Med Assoc; 2020 Sep; 119(9):1448-1449. PubMed ID: 32165088 [No Abstract] [Full Text] [Related]
58. Accidental pregnancy exposure to verteporfin: obstetrical and neonatal outcomes: a case report. Rodrigues M; Meira D; Batista S; Carrilho MM Aust N Z J Obstet Gynaecol; 2009 Apr; 49(2):236-7. PubMed ID: 19432621 [No Abstract] [Full Text] [Related]